{"id":"open-label-rusfertide","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rusfertide works by binding to the erythropoietin receptor, stimulating erythropoiesis and increasing red blood cell production. This can help alleviate anemia in patients with chronic kidney disease. By increasing red blood cell mass, rusfertide may also improve exercise capacity and quality of life in these patients.","oneSentence":"Rusfertide is a human erythropoietin receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:31.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease-associated anemia"}]},"trialDetails":[{"nctId":"NCT04202965","phase":"PHASE2","title":"PTG-300 in Subjects With Hereditary Hemochromatosis","status":"COMPLETED","sponsor":"Protagonist Therapeutics, Inc.","startDate":"2020-03-19","conditions":"Hereditary Hemochromatosis","enrollment":16},{"nctId":"NCT05210790","phase":"PHASE3","title":"A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Protagonist Therapeutics, Inc.","startDate":"2022-04-01","conditions":"Polycythemia Vera","enrollment":293},{"nctId":"NCT06033586","phase":"PHASE3","title":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Protagonist Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Polycythemia Vera","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Open-label rusfertide","genericName":"Open-label rusfertide","companyName":"Protagonist Therapeutics, Inc.","companyId":"protagonist-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rusfertide is a human erythropoietin receptor agonist. Used for Chronic kidney disease-associated anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}